JP2020510668A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510668A5
JP2020510668A5 JP2019547579A JP2019547579A JP2020510668A5 JP 2020510668 A5 JP2020510668 A5 JP 2020510668A5 JP 2019547579 A JP2019547579 A JP 2019547579A JP 2019547579 A JP2019547579 A JP 2019547579A JP 2020510668 A5 JP2020510668 A5 JP 2020510668A5
Authority
JP
Japan
Prior art keywords
carbonitrile
pyrrolo
pyrazol
pyrimidin
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019547579A
Other languages
English (en)
Japanese (ja)
Other versions
JP6978507B2 (ja
JP2020510668A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/062148 external-priority patent/WO2018094137A1/en
Publication of JP2020510668A publication Critical patent/JP2020510668A/ja
Publication of JP2020510668A5 publication Critical patent/JP2020510668A5/ja
Priority to JP2021183048A priority Critical patent/JP7360434B2/ja
Application granted granted Critical
Publication of JP6978507B2 publication Critical patent/JP6978507B2/ja
Priority to JP2023169299A priority patent/JP7592814B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019547579A 2016-11-18 2017-11-17 Cftr増強物質としてのピロロピリミジン Active JP6978507B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021183048A JP7360434B2 (ja) 2016-11-18 2021-11-10 Cftr増強物質としてのピロロピリミジン
JP2023169299A JP7592814B2 (ja) 2016-11-18 2023-09-29 Cftr増強物質としてのピロロピリミジン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423919P 2016-11-18 2016-11-18
US62/423,919 2016-11-18
PCT/US2017/062148 WO2018094137A1 (en) 2016-11-18 2017-11-17 Pyrrolopyrimidines as cftr potentiators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021183048A Division JP7360434B2 (ja) 2016-11-18 2021-11-10 Cftr増強物質としてのピロロピリミジン

Publications (3)

Publication Number Publication Date
JP2020510668A JP2020510668A (ja) 2020-04-09
JP2020510668A5 true JP2020510668A5 (OSRAM) 2020-12-17
JP6978507B2 JP6978507B2 (ja) 2021-12-08

Family

ID=62144793

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019547579A Active JP6978507B2 (ja) 2016-11-18 2017-11-17 Cftr増強物質としてのピロロピリミジン
JP2021183048A Active JP7360434B2 (ja) 2016-11-18 2021-11-10 Cftr増強物質としてのピロロピリミジン
JP2023169299A Active JP7592814B2 (ja) 2016-11-18 2023-09-29 Cftr増強物質としてのピロロピリミジン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021183048A Active JP7360434B2 (ja) 2016-11-18 2021-11-10 Cftr増強物質としてのピロロピリミジン
JP2023169299A Active JP7592814B2 (ja) 2016-11-18 2023-09-29 Cftr増強物質としてのピロロピリミジン

Country Status (22)

Country Link
US (5) US10301315B2 (OSRAM)
EP (2) EP4424311A3 (OSRAM)
JP (3) JP6978507B2 (OSRAM)
KR (2) KR102824092B1 (OSRAM)
CN (2) CN115850268B (OSRAM)
AU (2) AU2017362350B2 (OSRAM)
CA (1) CA3044050A1 (OSRAM)
CL (1) CL2019001334A1 (OSRAM)
CO (1) CO2019005993A2 (OSRAM)
CR (1) CR20190292A (OSRAM)
DO (1) DOP2019000126A (OSRAM)
EC (1) ECSP19043120A (OSRAM)
ES (1) ES2983686T3 (OSRAM)
IL (3) IL314404B1 (OSRAM)
MX (2) MX2021012639A (OSRAM)
PE (1) PE20200739A1 (OSRAM)
PH (1) PH12019501098A1 (OSRAM)
PL (1) PL3541390T3 (OSRAM)
RU (2) RU2757457C2 (OSRAM)
SG (1) SG10202106949XA (OSRAM)
UA (1) UA125400C2 (OSRAM)
WO (1) WO2018094137A1 (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
IL313498A (en) 2014-10-06 2024-08-01 Vertex Pharma Modulators of the cystic fibrosis transmembrane conductance regulator
WO2017112853A1 (en) * 2015-12-22 2017-06-29 Proteostasis Therapeutics, Inc. Methods of treating pulmonary diseases and disorders
HRP20211683T1 (hr) 2016-09-30 2022-03-04 Vertex Pharmaceuticals Incorporated Modulator transmembranskog regulatora provodljivosti cistične fibroze, farmaceutski pripravci, postupci liječenja, i postupak za pripravu modulatora
AU2017362350B2 (en) * 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators
MX2021013639A (es) 2016-12-09 2022-09-30 Vertex Pharma Forma cristalina del compuesto 1, un modulador del regulador de conductancia transmembrana de fibrosis quística, procesos para su preparación, composiciones farmacéuticas del compuesto 1, y su uso en el tratamiento de fibrosis quística.
CN110300589B (zh) * 2016-12-16 2023-03-10 囊性纤维化基金会 作为cftr增效剂的双环异杂芳基衍生物
AU2018279646B2 (en) 2017-06-08 2023-04-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
AU2018304168B2 (en) 2017-07-17 2023-05-04 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
US11465985B2 (en) 2017-12-08 2022-10-11 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
LT3752510T (lt) 2018-02-15 2023-04-11 Vertex Pharmaceuticals Incorporated Makrocikliniai junginiai kaip cistinės fibrozės transmembraninio laidumo reguliatoriaus moduliatoriai, jų farmacinės kompozicijos, jų panaudojimas cistinės fibrozės gydymui ir jų gamybos būdas
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
EP3980121A1 (en) * 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
MX2022000549A (es) 2019-07-15 2022-02-10 Novartis Ag Formulaciones de (s)-3-amino-6-metoxi-n-(3,3,3-trifluoro-2-hidroxi -2-metilpropil)-5-(trifluorometil)picolinamida.
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
US11584761B2 (en) 2019-08-14 2023-02-21 Vertex Pharmaceuticals Incorporated Process of making CFTR modulators
EP4013760A1 (en) 2019-08-14 2022-06-22 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
CN111138439B (zh) * 2020-01-17 2021-06-25 厦门大学 氟代吡咯并嘧啶类化合物及其制备方法和应用
US20230192700A1 (en) 2020-03-06 2023-06-22 Bayer Aktiengesellschaft Pyrazolopyrazines acting on cancers via inhibition of cdk12
KR20230052954A (ko) 2020-08-20 2023-04-20 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 점액 과다분비를 특징으로 하는 호흡기 질환의 치료 방법
AU2021397294A1 (en) 2020-12-10 2023-07-06 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
TW202425990A (zh) * 2022-11-02 2024-07-01 南韓商日東製藥股份有限公司 包含cftr調節劑化合物之點眼用組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ286892B6 (en) * 1992-12-17 2000-07-12 Pfizer Pyrrolopyrimidine compounds, intermediates for their preparation and pharmaceutical preparations based thereon
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
AU2002310187A1 (en) 2001-05-30 2002-12-09 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1730148A4 (en) * 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
TW201307354A (zh) * 2005-12-29 2013-02-16 Abbott Lab 蛋白質激酶抑制劑
EP2007767B1 (en) * 2006-03-11 2011-11-02 Vernalis (R&D) Ltd Pyrrolopyrimidine derivatives used as hsp90 inhibitors
AU2007347115A1 (en) * 2006-04-04 2008-10-23 The Regents Of The University Of California PI3 kinase antagonists
CN101917999A (zh) * 2007-11-07 2010-12-15 弗尔德里克斯制药股份有限公司 蛋白质运输的调节
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
WO2013071232A1 (en) 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules
US8828998B2 (en) * 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014060431A1 (en) * 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2015091532A1 (en) * 2013-12-19 2015-06-25 Almirall, S.A. Pyrrolopyrimidine derivatives as pi3k inhibitors
AU2017362350B2 (en) 2016-11-18 2021-12-23 Cystic Fibrosis Foundation Pyrrolopyrimidines as CFTR potentiators

Similar Documents

Publication Publication Date Title
JP2020510668A5 (OSRAM)
USD786655S1 (en) Carabiner
USD809988S1 (en) Leveling block
USD809987S1 (en) Leveling block
USD728654S1 (en) Network camera
USD739509S1 (en) L-type pipe fitting
USD796621S1 (en) TMX reticle
USD763601S1 (en) T-roll pillow
RU2021102805A (ru) 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
JP2013173781A5 (OSRAM)
USD755903S1 (en) Building block
USD724503S1 (en) Front bumper
USD784709S1 (en) Interlocking block for artwork
JP2017520613A5 (OSRAM)
CN110139865A (zh) Fgfr抑制剂
CA2902403C (en) Pde3/pde4 inhibitor/muscarinic receptor antagonist combination
LT3986561T (lt) Pirido[2,3-d]pirimidino dariniai kaip žmogaus imunodeficito viruso replikacijos inhibitoriai
USD859668S1 (en) Back roll spinal brace support
USD754551S1 (en) Locating and tracking tool
MX2016001639A (es) Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1).
HK1254343A1 (zh) 药物制剂
USD755904S1 (en) Building block
USD754260S1 (en) Building block
CN109843873A (zh) 炔代杂环化合物、其制备方法及其在医药学上的应用
EP4233846A3 (en) Pharmaceutical formulations